BRAT1 and esophageal squamous cell carcinoma: AlphaLISA analysis was performed on HDs and patients with ESCC, GC, and CRC to establish whether serum BRAT1-Ab is a novel serum biomarker of these GI cancers (Figure 5A and Table 4).